JP2010539172A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539172A5 JP2010539172A5 JP2010524889A JP2010524889A JP2010539172A5 JP 2010539172 A5 JP2010539172 A5 JP 2010539172A5 JP 2010524889 A JP2010524889 A JP 2010524889A JP 2010524889 A JP2010524889 A JP 2010524889A JP 2010539172 A5 JP2010539172 A5 JP 2010539172A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- toxoid
- clostridium difficile
- sodium
- sucrose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97249607P | 2007-09-14 | 2007-09-14 | |
| US60/972,496 | 2007-09-14 | ||
| PCT/US2008/010767 WO2009035707A1 (en) | 2007-09-14 | 2008-09-15 | Pharmaceutical compositions containing clostridium difficile toxoids a and b |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013241821A Division JP6258674B2 (ja) | 2007-09-14 | 2013-11-22 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539172A JP2010539172A (ja) | 2010-12-16 |
| JP2010539172A5 true JP2010539172A5 (enExample) | 2011-04-21 |
| JP5503543B2 JP5503543B2 (ja) | 2014-05-28 |
Family
ID=40452372
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524889A Active JP5503543B2 (ja) | 2007-09-14 | 2008-09-15 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| JP2013241821A Active JP6258674B2 (ja) | 2007-09-14 | 2013-11-22 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| JP2016212540A Pending JP2017052773A (ja) | 2007-09-14 | 2016-10-31 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013241821A Active JP6258674B2 (ja) | 2007-09-14 | 2013-11-22 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
| JP2016212540A Pending JP2017052773A (ja) | 2007-09-14 | 2016-10-31 | クロストリジウム・ディフィシレトキソイドａおよびｂを含有する薬学的組成物 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9320790B2 (enExample) |
| EP (3) | EP4537849A3 (enExample) |
| JP (3) | JP5503543B2 (enExample) |
| KR (2) | KR101679812B1 (enExample) |
| CN (2) | CN106039299A (enExample) |
| AU (1) | AU2008299885C1 (enExample) |
| BR (1) | BRPI0816790A8 (enExample) |
| CA (1) | CA2699435A1 (enExample) |
| CY (1) | CY1119979T1 (enExample) |
| DK (1) | DK2198007T3 (enExample) |
| ES (2) | ES3001561T3 (enExample) |
| HR (1) | HRP20180054T1 (enExample) |
| HU (1) | HUE037932T2 (enExample) |
| IL (1) | IL204366A (enExample) |
| MX (1) | MX2010002815A (enExample) |
| NO (1) | NO2198007T3 (enExample) |
| PL (1) | PL2198007T3 (enExample) |
| PT (1) | PT2198007T (enExample) |
| RU (1) | RU2550271C2 (enExample) |
| SI (1) | SI2198007T1 (enExample) |
| WO (1) | WO2009035707A1 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008299885C1 (en) | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| KR101907434B1 (ko) | 2010-09-03 | 2018-10-12 | 발네바 오스트리아 게엠베하 | C. 디피실의 a 독소 및 b 독소 단백질의 분리된 폴리펩타이드 및 이의 용도 |
| GB201105981D0 (en) * | 2011-04-08 | 2011-05-18 | Glaxosmithkline Biolog Sa | Novel process |
| AR086199A1 (es) * | 2011-04-22 | 2013-11-27 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| KR101135486B1 (ko) * | 2011-05-25 | 2012-04-13 | 함종욱 | 보툴리눔 에이형 독소의 액상제품 |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| KR102149206B1 (ko) | 2012-11-08 | 2020-08-31 | 세센 바이오, 아이엔씨. | 인터루킨-6의 길항제 및 이의 용도 |
| EP2928489B1 (en) | 2012-12-05 | 2019-02-27 | GlaxoSmithKline Biologicals S.A. | Immunogenic composition |
| US10137186B2 (en) | 2013-03-14 | 2018-11-27 | Takeda Vaccines, Inc. | Compositions and methods for live, attenuated alphavirus formulations |
| HK1213917A1 (zh) * | 2013-03-15 | 2016-07-15 | Sanofi Pasteur, Inc. | 類霉素、組合物及相關方法 |
| KR20150133770A (ko) * | 2013-03-15 | 2015-11-30 | 사노피 파스퇴르 인코포레이티드 | 톡소이드, 조성물 및 관련 방법 |
| SG11201510166YA (en) | 2013-06-14 | 2016-01-28 | Sanofi Pasteur Inc | Compositions and methods of immunizing against c. difficile |
| RS57864B1 (sr) | 2013-06-17 | 2018-12-31 | De Staat Der Nederlanden Vert Door De Minister Van Vws Ministerie Van Volksgezondheid Welzijn En Spo | Postupci za sprečavanje agregacije virusnih komponenti |
| US9930893B2 (en) * | 2014-02-10 | 2018-04-03 | The Johns Hopkins University | Inhibitors of DXP synthase and methods of use thereof |
| SI3215530T1 (sl) | 2014-11-07 | 2020-02-28 | Sesen Bio, Inc. | Izboljšana protitelesa IL-6 |
| BR112017024443A2 (pt) | 2015-05-15 | 2018-10-23 | Sanofi Pasteur Inc | métodos para imunização contra clostridium difficile |
| BE1023343B1 (nl) * | 2015-05-20 | 2017-02-09 | Mycartis Nv | Opslagbuffer |
| BR112018017031A2 (pt) | 2016-02-23 | 2019-01-22 | Sesen Bio Inc | formulações de antagonista de il-6 e usos das mesmas |
| JP7217700B2 (ja) | 2016-09-13 | 2023-02-03 | アラーガン、インコーポレイテッド | 安定化非タンパク質クロストリジウム毒素組成物 |
| JP7549530B2 (ja) * | 2018-05-21 | 2024-09-11 | 中外製薬株式会社 | ガラス容器に封入された凍結乾燥製剤 |
| WO2021255690A2 (en) * | 2020-06-19 | 2021-12-23 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
| AU2023393199A1 (en) * | 2022-12-13 | 2025-05-29 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4879218A (en) * | 1982-09-13 | 1989-11-07 | Virginia Tech Intellectual Properties, Inc. | Antibody for C.difficile |
| US5736139A (en) | 1989-10-31 | 1998-04-07 | Ochidian Pharmaceuticals, Inc. | Treatment of Clostridium difficile induced disease |
| JPH03193735A (ja) | 1989-12-22 | 1991-08-23 | Shionogi & Co Ltd | グリコペプチド系抗生物質の安定化組成物 |
| WO1993007904A1 (en) * | 1991-10-16 | 1993-04-29 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
| EP0654040A1 (en) | 1992-06-23 | 1995-05-24 | Interactive Biologics Associates | Pharmaceutical composition containing botulinum b complex |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| US5902565A (en) * | 1993-12-24 | 1999-05-11 | Csl Limited | Spray dried vaccine preparation comprising aluminium adsorbed immunogens |
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| JPH08333277A (ja) | 1995-06-05 | 1996-12-17 | Hoechst Japan Ltd | ヒト血液凝固第ｘｉｉｉ因子の安定化された水性液製剤 |
| JPH11510793A (ja) * | 1995-07-07 | 1999-09-21 | オラバックス インク． | 胃腸病に対する鼻腔内ワクチン接種 |
| US5932223A (en) | 1996-09-26 | 1999-08-03 | Merck & Co., Inc. | Rotavirus vaccine formulations |
| ATE346931T1 (de) * | 1997-06-20 | 2006-12-15 | Intervet Int Bv | Clostridium perfringens impfstoff |
| US6969520B2 (en) * | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
| EP2305303A3 (en) | 1997-10-20 | 2013-11-13 | Sanofi Pasteur Biologics Co. | Immunization against Clostridium difficile disease |
| EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
| US6013635A (en) * | 1998-05-28 | 2000-01-11 | Synsorb Biotech, Inc. | Treatment of C. difficile toxin B associated conditions |
| JP2000117967A (ja) * | 1998-10-16 | 2000-04-25 | Fuji Photo Film Co Ltd | インクジェット記録方法 |
| FR2791895B1 (fr) | 1999-03-23 | 2001-06-15 | Pasteur Merieux Serums Vacc | Utilisation de trehalose pour stabiliser un vaccin liquide |
| DK1187629T3 (da) * | 1999-04-19 | 2005-01-17 | Glaxosmithkline Biolog Sa | Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid |
| US6599715B1 (en) | 1999-05-12 | 2003-07-29 | The Regents Of The University Of California | Real time viability detection of bacterial spores |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| WO2003068260A1 (fr) | 2002-02-14 | 2003-08-21 | Chugai Seiyaku Kabushiki Kaisha | Produits pharmaceutiques en solution contenant des anticorps |
| AU2003225057A1 (en) * | 2002-04-19 | 2003-11-03 | The Regents Of The University Of Michigan | Polymer compositions that stabilize and control the release of formaldehyde-treated vaccine antigens |
| US20040235139A1 (en) * | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
| DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| WO2005035573A1 (ja) | 2003-10-09 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | タンパク質溶液の安定化方法 |
| EP1786459B1 (en) * | 2004-07-26 | 2014-02-12 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition whit a botulinum neurotoxin |
| WO2006044577A1 (en) | 2004-10-13 | 2006-04-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle |
| FR2881139A1 (fr) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Composition pour la lyophilisation de proteines |
| US8137677B2 (en) | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| BRPI0613001B8 (pt) | 2005-10-06 | 2021-05-25 | Allergan Inc | composições farmacêuticas de toxina clostrídica estabilizada por uma não-proteína |
| WO2007044809A2 (en) * | 2005-10-11 | 2007-04-19 | Botulinum Toxin Research Associates, Inc. | Albumin-free botulinum toxin based pharmaceutical compositions containing a hyaluronidase and methods of use |
| CN101808657A (zh) | 2006-11-07 | 2010-08-18 | 赛诺菲巴斯德生物制剂公司 | 冻干法稳定疫苗 |
| AU2008299885C1 (en) | 2007-09-14 | 2015-06-25 | Sanofi Pasteur Biologics, Llc | Pharmaceutical compositions containing clostridium difficile toxoids A and B |
| AU2009324180A1 (en) | 2008-12-03 | 2010-06-10 | Boehringer Ingelheim Vetmedica Gmbh | Process for production of vaccines |
-
2008
- 2008-09-15 AU AU2008299885A patent/AU2008299885C1/en not_active Ceased
- 2008-09-15 CN CN201610227574.1A patent/CN106039299A/zh active Pending
- 2008-09-15 RU RU2010114730/10A patent/RU2550271C2/ru not_active IP Right Cessation
- 2008-09-15 HU HUE08830210A patent/HUE037932T2/hu unknown
- 2008-09-15 JP JP2010524889A patent/JP5503543B2/ja active Active
- 2008-09-15 EP EP24220340.4A patent/EP4537849A3/en not_active Withdrawn
- 2008-09-15 PT PT88302104T patent/PT2198007T/pt unknown
- 2008-09-15 ES ES16174817T patent/ES3001561T3/es active Active
- 2008-09-15 ES ES08830210.4T patent/ES2657485T3/es active Active
- 2008-09-15 HR HRP20180054TT patent/HRP20180054T1/hr unknown
- 2008-09-15 SI SI200831906T patent/SI2198007T1/en unknown
- 2008-09-15 WO PCT/US2008/010767 patent/WO2009035707A1/en not_active Ceased
- 2008-09-15 KR KR1020107007994A patent/KR101679812B1/ko not_active Expired - Fee Related
- 2008-09-15 KR KR1020157036693A patent/KR20160005378A/ko not_active Abandoned
- 2008-09-15 CA CA2699435A patent/CA2699435A1/en not_active Abandoned
- 2008-09-15 US US12/677,864 patent/US9320790B2/en active Active
- 2008-09-15 NO NO08830210A patent/NO2198007T3/no unknown
- 2008-09-15 CN CN200880116603.0A patent/CN101855336B/zh active Active
- 2008-09-15 PL PL08830210T patent/PL2198007T3/pl unknown
- 2008-09-15 BR BRPI0816790A patent/BRPI0816790A8/pt not_active IP Right Cessation
- 2008-09-15 EP EP08830210.4A patent/EP2198007B1/en not_active Not-in-force
- 2008-09-15 MX MX2010002815A patent/MX2010002815A/es unknown
- 2008-09-15 EP EP16174817.3A patent/EP3124044B8/en active Active
- 2008-09-15 DK DK08830210.4T patent/DK2198007T3/en active
-
2010
- 2010-03-09 IL IL204366A patent/IL204366A/en active IP Right Grant
-
2013
- 2013-11-22 JP JP2013241821A patent/JP6258674B2/ja active Active
-
2016
- 2016-03-29 US US15/083,428 patent/US9687541B2/en active Active
- 2016-10-31 JP JP2016212540A patent/JP2017052773A/ja active Pending
-
2017
- 2017-06-26 US US15/632,480 patent/US10639362B2/en active Active
-
2018
- 2018-01-23 CY CY20181100084T patent/CY1119979T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2010114730A (ru) | Фармацевтические композиции, содержащие анатоксины а и в clostridium difficile | |
| EP2709657B1 (en) | Thermostable vaccine compositions and methods of preparing same | |
| Ohtake et al. | Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines | |
| JP4902103B2 (ja) | 凍結乾燥フォームによる生物活性材料の保存 | |
| US12318440B2 (en) | VLP stabilized vaccine compositions | |
| JP2014139229A5 (enExample) | ||
| US8216588B2 (en) | Lyophilized preparation comprising influenza vaccine, and method for preparation thereof | |
| JP2012531442A5 (enExample) | ||
| KR20190028555A (ko) | 비강내 전달을 위한 방법 및 조성물 | |
| CN104367558A (zh) | 一种奥司他韦冻干口崩片及其制备方法 | |
| JP2015531377A5 (enExample) | ||
| CN106794145A (zh) | 热稳定冻干轮状病毒疫苗制剂及其制备方法 | |
| RU2014151424A (ru) | Термостабильные составы вакцины | |
| US11224571B2 (en) | Oral dispersible vaccine comprising virosomes | |
| BE1024685B1 (fr) | Compositions | |
| JP2018514564A5 (enExample) | ||
| TW201625296A (zh) | 發泡性降低之疫苗組合物 | |
| US10857106B2 (en) | Methods and products for treating and/or delaying onset of dysplastic lesions | |
| US10973900B2 (en) | Dried composition | |
| US20230060631A1 (en) | Dry liposome adjuvant-containing vaccines and related methods thereof | |
| JPWO2023120535A5 (enExample) | ||
| TH2001003124A (th) | สูตรผสมขององค์ประกอบวัคซีนไวรัสเดงกี | |
| RU2457855C2 (ru) | Противовирусная и антимикробная композиция | |
| Kraan | Novel formulations and delivery strategies for inactivated polio vaccines: new routes with benefits | |
| Cyr | Novel intranasal proteosome-based respiratory syncytial virus (RSV) vaccines elicit protection in mice without the risk of enhanced pathology or eosinophila by triggering innate immune pathways |